Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
11.5.2022 16:00:00 EEST | Business Wire | Press release
Alira Health (www.alirahealth.com), a global healthcare advisory and technology company, today announced the acquisition of RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction were not disclosed.
RedCrow was launched in 2016 by Brian Smith, a former Morgan Stanley financial advisor, and Jerry Harrison, an entrepreneur and member of the Rock and Roll Hall of Fame with Talking Heads. RedCrow mines the “wisdom of the crowd” to help find companies that resonate with an audience that may not only use a product but also invest in and realize a return from the company that invented it. This acquisition extends Alira Health’s ability to partner with patients across the lifecycle of drug and device development into the financing phase for early-stage pharma, MedTech, and healthcare services solutions.
“From personal experience, the founders at RedCrow recognize that not every drug or device receives the right investment,” said Gabriele Brambilla, CEO, and founder of Alira Health. “By reinventing and democratizing the way early-stage companies get funded, RedCrow helps more healthcare solutions come to market that can save patients’ lives. Alira Health already partners with patients across the development lifecycle. With RedCrow, we can now involve patients, their care circles, and other investors in the financing phase for new products that may also improve their care outcomes.”
RedCrow’s Brian Smith added, “We founded RedCrow with the belief that healthcare investing should be more immediate, transparent, and accessible, and that patients and their family members should be able to help fund future developments that may impact their own care. We embrace Alira Health’s mission to humanize healthcare and view our platform as a natural extension of Alira Health’s business model. At the same time, early-stage companies on the RedCrow platform can benefit from the breadth of Alira Health’s extensive services offering.”
Since its founding, RedCrow has marketed over 250 fundraises totaling $250 million. Recent success stories include HeartBeam (NASDAQ: BEAT), Sen Jam Pharmaceutical, Activ Surgical and Centerline Biomedical.
About RedCrow
Headquartered in Mill Valley, Calif., RedCrow, which was created because of the 2012 Jobs Act, is a direct investment and marketing platform for healthcare innovation, providing curated deal flow for all investors. RedCrow leverages both the industry experts to provide comprehensive analysis on healthcare startups, enabling a wide array of investors to help healthcare innovation succeed. When a startup joins RedCrow, it's equipped with the tools it needs, like virtual deal rooms, to market its company and investment opportunity. RedCrow leverages the knowledge of its advisory board, which includes financial, scientific, and medical professionals, along with its online community of investors, healthcare professionals, and patients to identify and support innovative companies.
Learn more at https://www.redcrow.com/home/what-we-do.html. Follow RedCrow on Twitter (@RedCrowCrowd) at https://twitter.com/RedCrowCrowd and LinkedIn at https://www.linkedin.com/company/redcrow-crowd/.
About Alira Health
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.
Learn more at https://alirahealth.com/. Follow Alira Health on Twitter (@AliraHealth) at https://twitter.com/alirahealth and LinkedIn at https://www.linkedin.com/company/alira-health/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005026/en/
Contact information
Corporate
Susan Irving
Vice President of Global Marketing
susan.irving@alirahealth.com
Media
David Schull
President, Russo Partners LLC
david.schull@russopartnersllc.com
Olipriya Das
Senior Account Executive, Russo Partners LLC
olipriya.das@russopartnersllc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom